Drug Discovery for Overcoming Chronic Kidney Disease (CKD): Development of Drugs on Endothelial Cell Protection for Overcoming CKD

Chronic kidney disease (CKD) is becoming a major public health problem worldwide. It is important to protect endothelial function in CKD treatment because injury of the endothelium is a critical event for the generation and progression of CKD. Recently, clinical studies showed that nifedipine, an an...

Full description

Saved in:
Bibliographic Details
Main Authors: Keisuke Ishizawa (Author), Kunihisa Yamaguchi (Author), Yuya Horinouchi (Author), Yayoi Fukuhara (Author), Soichiro Tajima (Author), Shuichi Hamano (Author), Shuhei Tomita (Author), Koichiro Tsuchiya (Author), Toshiaki Tamaki (Author)
Format: Book
Published: Elsevier, 2009-01-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_fb4e0cfa7a6840d08a7e86a58ebfb60f
042 |a dc 
100 1 0 |a Keisuke Ishizawa  |e author 
700 1 0 |a Kunihisa Yamaguchi  |e author 
700 1 0 |a Yuya Horinouchi  |e author 
700 1 0 |a Yayoi Fukuhara  |e author 
700 1 0 |a Soichiro Tajima  |e author 
700 1 0 |a Shuichi Hamano  |e author 
700 1 0 |a Shuhei Tomita  |e author 
700 1 0 |a Koichiro Tsuchiya  |e author 
700 1 0 |a Toshiaki Tamaki  |e author 
245 0 0 |a Drug Discovery for Overcoming Chronic Kidney Disease (CKD): Development of Drugs on Endothelial Cell Protection for Overcoming CKD 
260 |b Elsevier,   |c 2009-01-01T00:00:00Z. 
500 |a 1347-8613 
500 |a 10.1254/jphs.08R08FM 
520 |a Chronic kidney disease (CKD) is becoming a major public health problem worldwide. It is important to protect endothelial function in CKD treatment because injury of the endothelium is a critical event for the generation and progression of CKD. Recently, clinical studies showed that nifedipine, an antihypertensive drug, acts as a protective agent of endothelial cells (ECs). Nifedipine is reported to partially decompose to a nitrosonifedipine that has high reactivity against lipid-derived radicals in vitro. However, it is still unclear whether nitrosonifedipine is a biologically active agent against endothelial injury. We observed that nitrosonifedipine was converted to radical form by reaction with cultured ECs. The cumene hydroperoxide mediated cytotoxity was reduced by nitrosonifedipine in cultured human glomerular ECs (HGECs). Also nitrosonifedipine suppressed the expression of TNF-α-induced intercellular cell adhesion molecule-1 in HGECs. Chronic administration of Nω-nitro-L-arginine methyl ester (L-NAME) caused systemic arterial hypertension, endotherial injury, and renal dysfunction. In L-NAME- induced hypertensive rats, nitrosonifedipine treatment improved not only the acetylcholine-induced vasodilation of the aortic rings, but also renal dysfunction such as increasing the levels of serum creatinine and urinary protein excretion. Our preliminary data suggest that nitrosonifedipine is a new and useful drug for the treatment of CKD involving ameliorating effects on EC disorder. Keywords:: chronic kidney disease (CKD), endothelial dysfunction, nitrosonifedipine, antioxidative effect 
546 |a EN 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Journal of Pharmacological Sciences, Vol 109, Iss 1, Pp 14-19 (2009) 
787 0 |n http://www.sciencedirect.com/science/article/pii/S1347861319312903 
787 0 |n https://doaj.org/toc/1347-8613 
856 4 1 |u https://doaj.org/article/fb4e0cfa7a6840d08a7e86a58ebfb60f  |z Connect to this object online.